Real-world outcomes post-transition to once-every-3-months paliperidone palmitate in patients with schizophrenia within US commercial plans

导出原文传递

翻译打印收藏纠错

作者： Emond, Bruno ^[1] ; El Khoury, Antoine C. ^[2] ; Patel, Charmi ; Pilon, Dominic ; Morrison, Laura ; Zhdanava, Maryia ; Lefebvre, Patrick ; Tandon, Neeta ; Joshi, Kruti

作者单位： Janssen Sci Affairs LLC, Titusville, NJ 08560 USA ^[1] Anal Grp Inc, Montreal, PQ, Canada ^[2]

关键词 Paliperidone palmitate Antipsychotic agents Schizophrenia Medication adherence Delivery of healthcare Healthcare costs

发布时间 2019-09-17

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Current medical research and opinion

2019年35卷3期

407-416页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Real-world outcomes post-transition to once-every-3-months paliperidone palmitate in patients with schizophrenia within US commercial plans

Current medical research and opinion

相似文献

Current medical research and opinion

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Real-world outcomes post-transition to once-every-3-months paliperidone palmitate in patients with schizophrenia within US commercial plans

Current medical research and opinion

相似文献

Current medical research and opinion

相关期刊

检索历史清除